Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, in patients with relapsed or refractory B-cell malignancies, alone or in combination with a Janus kinase 1 inhibitor (itacitinib) or chemotherapy...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood
Main Authors: Forero-Torres, Andres, Ramchandren, Radhakrishnan, Yacoub, Abdulraheem, Wertheim, Michael S., Edenfield, William J., Caimi, Paolo, Gutierrez, Martin, Akard, Luke, Escobar, Carolina, Call, Justin, Persky, Daniel, Iyer, Swaminathan, DeMarini, Douglas J., Zhou, Li, Chen, Xuejun, Dawkins, Fitzroy, Phillips, Tycel J.
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2019
主題:
Lymphoid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6543513/
https://ncbi.nlm.nih.gov/pubmed/30803990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-08-867499
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍